(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 14.42% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.86%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Neurocrine Biosciences's revenue in 2025 is $2,355,300,000.On average, 11 Wall Street analysts forecast NBIX's revenue for 2025 to be $268,727,027,886, with the lowest NBIX revenue forecast at $261,489,050,343, and the highest NBIX revenue forecast at $274,927,490,526. On average, 9 Wall Street analysts forecast NBIX's revenue for 2026 to be $311,664,850,306, with the lowest NBIX revenue forecast at $296,877,221,995, and the highest NBIX revenue forecast at $337,026,835,283.
In 2027, NBIX is forecast to generate $351,230,699,443 in revenue, with the lowest revenue forecast at $324,802,185,837 and the highest revenue forecast at $416,072,788,524.